Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
OBSVF similar filings
- 28 Jun 22 ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
- 17 Jun 22 ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
- 27 May 22 ObsEva Announces Corporate Updates
- 19 May 22 ObsEva SA Announces that Shareholders Approved all Board Proposals at its
- 17 May 22 Index to Unaudited Condensed Consolidated Financial Statements
- 2 May 22 ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
- 25 Apr 22 ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
Filing view
External links